Affinity Asset Advisors, LLC Nautilus Biotechnology, Inc. Transaction History

Affinity Asset Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.13 $184,496 - $294,630	-94,131 Reduced 20.17%	372,476 $790,000
Q2 2022 Aug 12, 2022	SELL	$2.64 - $4.84 $243,967 - $447,274	-92,412 Reduced 16.53%	466,607 $1.26 Million
Q1 2022 May 13, 2022	SELL	$3.5 - $5.3 $1.72 Million - $2.6 Million	-490,702 Reduced 46.75%	559,019 $2.43 Million
Q4 2021 Feb 11, 2022	BUY	$4.45 - $6.21 $332,508 - $464,017	74,721 Added 7.66%	1,049,721 $5.44 Million
Q3 2021 Nov 12, 2021	BUY	$6.14 - $10.1 $460,500 - $757,500	75,000 Added 8.33%	975,000 $5.99 Million

Q2 2021 Aug 13, 2021	BUY	$9.04 - $14.19 $8.14 Million - $12.8 Million	900,000 New	900,000 $9.09 Million

63.1M

14K

1.8K

Ticker NAUT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,663,000
Market Cap $284M
Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.